

NeuExcell Therapeutics Announces \$15 Million Series Pre-A+

May 11, 2023

Shanghai – May 11, 2023 – Cooley advised NeuExcell Therapeutics, a neurodegenerative disease gene therapy company, on its \$15 million+ Series Pre-A+ financing round. Partner Christina Zhang led the Cooley team.

Investors in the round included Shanghai Zhangjiang Leading Qifan Venture Capital, Jiangxi Jilixinsheng Enterprise Management, Fujian Haixi Pharmaceuticals, Suzhou Industrial Park Technology Innovation Investment, Suzhou Suxin Junnuo Venture Capital, Guangzhou Huiju Xinxing Equity Investment, Guangdong Jike Achievement Transformation Venture Capital Fund and Quanzhou Hongshi II Venture Capital. Proceeds from the financing round will fund NeuExcell's neural regeneration technology development.

NeuExcell is a privately held biotech company focusing on in vivo neural regeneration and repair using adeno-associated, virus-based gene therapy to improve the lives of patients suffering from neurodegenerative diseases and central nervous system injuries. The company's co-founder, chief scientific adviser and board director, professor Gong Chen, is an internationally renowned expert in regenerative medicine and was one of the first innovators to use brain endogenous astrocytes to directly transdifferentiate into functional neurons in situ in adult mammals. NeuExcell's senior management team comes from world-renowned pharmaceutical companies, such as Novartis, Pfizer, AstraZeneca, Sanofi and Spark Therapeutics, among others, and has rich experience in industrialization. Its pipeline covers major neurodegenerative diseases – including stroke, glioma, Huntington's disease, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, traumatic brain injury and spinal cord injury.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our [legal notices](#).

Key Contacts

Lunga Su Shanghai	lunga.su@cooley.com +86 21 6030 0663
----------------------	---

This information is a general description of the law; it is not intended to provide specific legal advice nor is it intended to create an attorney-client relationship with Cooley LLP. Before taking any action on this information you should seek professional counsel.

Copyright © 2023 Cooley LLP, 3175 Hanover Street, Palo Alto, CA 94304; Cooley (UK) LLP, 22 Bishopsgate, London, UK EC2N 4BQ. Permission is granted to make and redistribute, without charge, copies of this entire document provided that such copies are complete and unaltered and identify Cooley LLP as the author. All other rights reserved.